Literature DB >> 23196060

RNA aptamers targeting cancer stem cell marker CD133.

Sarah Shigdar1, Liang Qiao, Shu-Feng Zhou, Dongxi Xiang, Tao Wang, Yong Li, Lee Yong Lim, Lingxue Kong, Lianhong Li, Wei Duan.   

Abstract

The monoclonal antibody against the AC133 epitope of CD133 has been widely used as a cell surface marker of cancer stem cells in several different cancer types. Here, we describe the isolation and characterisation of two RNA aptamers, including the smallest described 15 nucleotide RNA aptamer, which specifically recognise the AC133 epitope and the CD133 protein with high sensitivity. As well, both these aptamers show superior tumour penetration and retention when compared to the AC133 antibody in a 3-D tumour sphere model. These novel CD133 aptamers will aid future development of cancer stem cell targeted therapeutics and molecular imaging. Crown
Copyright © 2012. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23196060     DOI: 10.1016/j.canlet.2012.11.032

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

Review 1.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

Review 2.  Novel methodologies in analysis of small molecule biomarkers and living cells.

Authors:  Yinan Chen; Zhenggang Zhu; Yingyan Yu
Journal:  Tumour Biol       Date:  2014-08-14

Review 3.  Therapeutic targeting of gastrointestinal cancer stem cells.

Authors:  Jonathan Stem; John C Flickinger; Dante Merlino; Ellen M Caparosa; Adam E Snook; Scott A Waldman
Journal:  Regen Med       Date:  2019-04-26       Impact factor: 3.806

4.  Aptamer identification of brain tumor-initiating cells.

Authors:  Youngmi Kim; Qiulian Wu; Petra Hamerlik; Masahiro Hitomi; Andrew E Sloan; Gene H Barnett; Robert J Weil; Patrick Leahy; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2013-06-24       Impact factor: 12.701

5.  Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.

Authors:  Hongran Yin; Gaofeng Xiong; Sijin Guo; Congcong Xu; Ren Xu; Peixuan Guo; Dan Shu
Journal:  Mol Ther       Date:  2019-04-25       Impact factor: 11.454

Review 6.  Drug-Tolerant Persister Cells in Cancer Therapy Resistance.

Authors:  Pavan Kumar Dhanyamraju; Todd D Schell; Shantu Amin; Gavin P Robertson
Journal:  Cancer Res       Date:  2022-07-18       Impact factor: 13.312

7.  Direct validation of aptamers as powerful tools to image solid tumor.

Authors:  Olivier Martínez; Elisabeth Bellard; Muriel Golzio; Saad Mechiche-Alami; Marie-Pierre Rols; Justin Teissié; Vincent Ecochard; Laurent Paquereau
Journal:  Nucleic Acid Ther       Date:  2014-02-03       Impact factor: 5.486

8.  An integrated microfluidic system for screening of phage-displayed peptides specific to colon cancer cells and colon cancer stem cells.

Authors:  Yu-Jui Che; Huei-Wen Wu; Lien-Yu Hung; Ching-Ann Liu; Hwan-You Chang; Kuan Wang; Gwo-Bin Lee
Journal:  Biomicrofluidics       Date:  2015-10-15       Impact factor: 2.800

9.  Delivery Of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer.

Authors:  Qi Ma; Wei Qian; Wei Tao; Yanling Zhou; Boxin Xue
Journal:  Drug Des Devel Ther       Date:  2019-11-28       Impact factor: 4.162

Review 10.  Aptamers: Cutting edge of cancer therapies.

Authors:  Sarah Shigdar; Brett Schrand; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2021-06-17       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.